Compassionate and optimum use of new tuberculosis drugs-Reference-Cited by-同舟云学术

Compassionate and optimum use of new tuberculosis drugs

Published:2015-10 Issue:10 Volume:15 Page:1131
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Reed Caitlin,Mason Leona,Cox Helen,Seaworth Barbara,Lessem Erica,Furin Jennifer

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference2 articles.

1. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects;Zumla;Lancet Infect Dis,2014

2. Shah NS, Brust JC, Mathema B, et al. Majority of XDR TB cases are due to transmission in a high-HIV-prevalence setting. 2015 Conference on retroviruses and opportunistic infections; Seattle, WA; Feb 23–24, 2015. Abstract 92.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addressing the needs of people with extensively drug-resistant TB through pre-approval access to drugs and research;Public Health Action;2023-12-01

2. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis;Frontiers in Microbiology;2021-10-07

3. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis;The International Journal of Tuberculosis and Lung Disease;2018-04-01

4. The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis;European Respiratory Journal;2018-03

5. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?;The Lancet Infectious Diseases;2017-12